Outlook Therapeutics Inc (OTLK)

[pfelgueiras]

Is Outlook Therapeutics (OTLK) Stock About To Start To Soar?
By Amsden Lindsay August 10, 2021, 10:01 AM (on InvestReader)

Outlook Therapeutics (NASDAQ: OTLK) stock has been running between $2 and $3 for most of this year. Last Tuesday, the company released a very important update, which pushed its stock to hit the $3 level again. So, is this stock about to start to soar?

Outlook Therapeutics is a biotech company that develops and commercializes various products for the healthcare market. ONS-5010 is the important one in its products, which is in Phase 3 clinical trial to treat retina diseases. The company reported positive efficacy and safety data from its Phase 3 NORSE TWO trial of ONS-5010. In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary and key secondary efficacy endpoints, and ONS-5010 was safe and well tolerated.

The company said that if ONS-5010 is successful, it will plan to submit for regulatory approval of ONS-5010 in multiple markets. Currently, there is currently no bevacizumab approved for ophthalmic indications in the United States. Globally, the nine major markets account for an estimated $13.1 billion market for anti-VEGF drugs to treat retina diseases. Anyway, that is the long-term potential of positive news surrounding this drug or trial. Therefore, OTLK stock is worth adding to your watchlist.